D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq: PPCB) in Connection with its $4,000,000 Uplisting
Transaction Information On August 19, 2025, Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel